Clinical Trial Update: CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing [Phase 4]

View source ↗

Summary

Phase 4 study assessing whether CYP2C19 genetic polymorphism affects the accuracy of proton-pump inhibitor testing in gastroesophageal reflux disease; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Snippet

Sponsor: National Taiwan University Hospital | Conditions: GERD | Phase 4 | Status: COMPLETED